Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 20 May 2020. Scott Whitaker.

Executive Summary

The decision to again postpone Medicare coverage for FDA-cleared breakthrough devices rule came as a disappointment to industry groups such as AdvaMed, though CEO Scott Whitaker continues to hope that the regulation will be put in place in December.

“While it’s certainly disappointing that a Medicare policy to help suffering seniors was delayed, we look forward to continuing to make the case that breakthrough medical technologies deemed safe and effective by the FDA should be quickly covered by Medicare. We remain hopeful that CMS will work with us to achieve this important goal of improving Medicare beneficiaries’ access to lifesaving treatments.” – Scott Whitaker, CEO, AdvaMed

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts